{"id":315624,"date":"2026-10-19T10:20:32","date_gmt":"2026-10-19T04:50:32","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=315624"},"modified":"2026-10-19T10:20:32","modified_gmt":"2026-10-19T04:50:32","slug":"gujarat-based-stocks-to-watch-multibagger-potential","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/","title":{"rendered":"3 Top Gujarat-based Stocks to Watch for Future Multibagger Potential: Torrent Pharma, Zydus Lifesciences and Astral"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Torrent Pharma Rs 4,558.90. Zydus Lifesciences Rs 1,123. Astral Rs 1,427.40. Market caps from Rs 38,753 crore to Rs 1.75 lakh crore. Data as of 16 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Torrent Pharma, Zydus Lifesciences and Astral are the 3 picks in this Gujarat-based stocks watchlist, with market caps between Rs 38,753 crore and Rs 1.75 lakh crore. Torrent Pharma stands out for the highest return on equity at 25.49%, while Zydus Lifesciences offers the lowest PE of the group at 24.78. PE ratios run from 24.78 to 81.26, so compare each one with its industry PE before investing. All figures are as of 16 October 2026.<\/p>\n<\/p><\/div>\n<p>Gujarat-based stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Torrent Pharma, Zydus Lifesciences and Astral meet that test, with market caps from Rs 38,753 crore to Rs 1.75 lakh crore and Torrent Pharma offering the highest return on equity at 25.49%. Gujarat&#8217;s business culture has produced strong pharma and building-products companies headquartered in Ahmedabad.<\/p>\n<p>This list covers listed companies headquartered in Ahmedabad, Gujarat, with complete, verifiable financials, ranked by market capitalisation. Not every name here is a largecap, so the list takes the leading companies of the sector by market capitalisation. Investors screening Gujarat-based stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 16 October 2026 and are drawn from NSE and BSE data and company filings.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=gujarat-based-stocks\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#What_Are_Gujarat-based_Stocks_and_Why_Do_They_Attract_Multibagger_Interest\" title=\"What Are Gujarat-based Stocks and Why Do They Attract Multibagger Interest?\">What Are Gujarat-based Stocks and Why Do They Attract Multibagger Interest?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#Gujarat-based_Stocks_at_a_Glance_Price_Market_Cap_PE_and_ROE\" title=\"Gujarat-based Stocks at a Glance: Price, Market Cap, PE and ROE\">Gujarat-based Stocks at a Glance: Price, Market Cap, PE and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#Torrent_Pharma_2879_Profit_CAGR_Since_FY22\" title=\"Torrent Pharma: 28.79% Profit CAGR Since FY22\">Torrent Pharma: 28.79% Profit CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#Zydus_Lifesciences_2124_Profit_CAGR_Since_FY22\" title=\"Zydus Lifesciences: 21.24% Profit CAGR Since FY22\">Zydus Lifesciences: 21.24% Profit CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#Astral_Debt-to-Equity_of_006\" title=\"Astral: Debt-to-Equity of 0.06\">Astral: Debt-to-Equity of 0.06<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#Gujarat-based_Stocks_Financial_Comparison_on_Growth_and_Margins\" title=\"Gujarat-based Stocks: Financial Comparison on Growth and Margins\">Gujarat-based Stocks: Financial Comparison on Growth and Margins<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#Institutional_Holding_in_Torrent_Pharma_Zydus_Lifesciences_and_Astral\" title=\"Institutional Holding in Torrent Pharma, Zydus Lifesciences and Astral\">Institutional Holding in Torrent Pharma, Zydus Lifesciences and Astral<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#Risks_to_Weigh_in_Gujarat-based_Stocks\" title=\"Risks to Weigh in Gujarat-based Stocks\">Risks to Weigh in Gujarat-based Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#How_to_Choose_Between_Gujarat-based_Stocks\" title=\"How to Choose Between Gujarat-based Stocks\">How to Choose Between Gujarat-based Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#Frequently_Asked_Questions_on_Gujarat-based_Stocks_to_Watch\" title=\"Frequently Asked Questions on Gujarat-based Stocks to Watch\">Frequently Asked Questions on Gujarat-based Stocks to Watch<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#Which_are_the_best_Gujarat-based_stocks_to_watch_for_multibagger_potential\" title=\"Which are the best Gujarat-based stocks to watch for multibagger potential?\">Which are the best Gujarat-based stocks to watch for multibagger potential?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#Is_Torrent_Pharma_a_good_stock_for_long-term_investors\" title=\"Is Torrent Pharma a good stock for long-term investors?\">Is Torrent Pharma a good stock for long-term investors?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#Can_Zydus_Lifesciences_become_a_multibagger_from_here\" title=\"Can Zydus Lifesciences become a multibagger from here?\">Can Zydus Lifesciences become a multibagger from here?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#What_is_the_market_cap_of_Torrent_Pharma_Zydus_Lifesciences_and_Astral\" title=\"What is the market cap of Torrent Pharma, Zydus Lifesciences and Astral?\">What is the market cap of Torrent Pharma, Zydus Lifesciences and Astral?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#What_are_the_risks_of_investing_in_Gujarat-based_stocks\" title=\"What are the risks of investing in Gujarat-based stocks?\">What are the risks of investing in Gujarat-based stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#Why_is_Torrent_Pharma_trading_at_a_PE_of_8126\" title=\"Why is Torrent Pharma trading at a PE of 81.26?\">Why is Torrent Pharma trading at a PE of 81.26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/gujarat-based-stocks-to-watch-multibagger-potential\/#How_much_do_institutions_hold_in_Torrent_Pharma_Zydus_Lifesciences_and_Astral\" title=\"How much do institutions hold in Torrent Pharma, Zydus Lifesciences and Astral?\">How much do institutions hold in Torrent Pharma, Zydus Lifesciences and Astral?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Gujarat-based_Stocks_and_Why_Do_They_Attract_Multibagger_Interest\"><\/span><strong>What Are Gujarat-based Stocks and Why Do They Attract Multibagger Interest?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Gujarat-based stocks are shares of companies headquartered in Ahmedabad, in a state known for business and industry. These companies sell medicines and plumbing products across India and in export markets.<\/p>\n<p>Strong brands, well run plants and steady demand have helped Gujarat-based firms grow. Companies with healthy margins and good returns on equity are the ones investors compare in Gujarat-based stocks.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Gujarat-based_Stocks_at_a_Glance_Price_Market_Cap_PE_and_ROE\"><\/span><strong>Gujarat-based Stocks at a Glance: Price, Market Cap, PE and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Prices are closing prices as of 16 October 2026. Zydus Lifesciences has the lowest PE of the group at 24.78, while Torrent Pharma posts the highest return on equity at 25.49%.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">PE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Industry PE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Debt to Equity<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">52-Week Range (Rs)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/torntpharm\/torrent-pharmaceuticals-ltd-share-price-today\">Torrent Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">4,558.90<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,75,196<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">81.26<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">36.42<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">25.49%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1.79<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">3,480.60 to 5,250.00<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/zyduslife\/zydus-lifesciences-ltd-share-price-today\">Zydus Lifesciences<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,123<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,13,790<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">24.78<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">36.42<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">18.59%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.46<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">835.50 to 1,232.10<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/astral\/astral-ltd-share-price-today\">Astral<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,427.40<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">38,753<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">67.31<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">36.61<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">13.18%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.06<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,311.60 to 1,768.70<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Torrent_Pharma_2879_Profit_CAGR_Since_FY22\"><\/span><strong>Torrent Pharma: 28.79% Profit CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Torrent Pharmaceuticals makes branded medicines for chronic therapies such as cardiac, gastro-intestinal and central nervous system care in India and overseas. It reported FY26 revenue of Rs 13,886.15 crore, up 20.34% year on year, and net profit of Rs 2,138.18 crore, up 11.87%. Net profit has compounded at 28.79% a year since FY22, while revenue has grown 12.38% a year. Operating margin was 22.70% in FY26.<\/p>\n<p>In the June 2026 quarter, revenue rose 56.29% to Rs 4,909 crore and net profit grew 3.28% to Rs 566 crore. The share price has gained 194.63% over five years and 29.72% over the past year. Domestic institutions raised their holding from 9.28% in September 2025 to 12.87% in July 2026. The stock trades at a PE of 81.26 against an industry PE of 36.42, with a return on equity of 25.49%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Zydus_Lifesciences_2124_Profit_CAGR_Since_FY22\"><\/span><strong>Zydus Lifesciences: 21.24% Profit CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Zydus Lifesciences develops and sells generic medicines, vaccines, consumer wellness products and specialty therapies. It reported FY26 revenue of Rs 27,657.90 crore, up 17.64% year on year, and net profit of Rs 5,026.40 crore, up 8.92%. Net profit has compounded at 21.24% a year since FY22, while revenue has grown 15.89% a year. Operating margin was 16.55% in FY26. The debt-to-equity ratio is 0.46.<\/p>\n<p>The stock trades at a PE of 24.78 against an industry PE of 36.42, below the sector average, with a return on equity of 18.59%. Revenue for the June 2026 quarter rose 20.72% to Rs 8,123.10 crore, at an operating margin of 25.86%. The share price has gained 113.38% over five years and 15.79% over the past year. Domestic institutions raised their holding from 10.86% in September 2025 to 11.28% in September 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Astral_Debt-to-Equity_of_006\"><\/span><strong>Astral: Debt-to-Equity of 0.06<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Astral makes CPVC and PVC pipes, fittings, adhesives and water tanks for plumbing and drainage in homes and buildings. It reported FY26 revenue of Rs 6,615.90 crore, up 12.64% year on year, and net profit of Rs 534.70 crore, up 3.04%. Revenue has compounded at 10.55% a year since FY22. Operating margin was 16.54% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.<\/p>\n<p>In the June 2026 quarter, revenue rose 16.09% to Rs 1,590.80 crore and net profit grew 51.77% to Rs 120.20 crore. Domestic institutions raised their holding from 14.90% in June 2025 to 21.31% in June 2026. The stock trades at a PE of 67.31 against an industry PE of 36.61, with a return on equity of 13.18%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Gujarat-based_Stocks_Financial_Comparison_on_Growth_and_Margins\"><\/span><strong>Gujarat-based Stocks: Financial Comparison on Growth and Margins<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table compares scale and growth across these Gujarat-based stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Revenue Growth (YoY)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">4-Year Revenue CAGR<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">4-Year Net Profit CAGR<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Operating Margin (Latest Quarter)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Torrent Pharma<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">13,886.15<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">2,138.18<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">20.34%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.38%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">28.79%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">33.73%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Zydus Lifesciences<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">27,657.90<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">5,026.40<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">17.64%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">15.89%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">21.24%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">25.86%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Astral<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">6,615.90<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">534.70<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.64%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">10.55%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">2.19%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">15.46%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data on these Gujarat-based stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Institutional_Holding_in_Torrent_Pharma_Zydus_Lifesciences_and_Astral\"><\/span><strong>Institutional Holding in Torrent Pharma, Zydus Lifesciences and Astral<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Institutional holding shows who is backing these Gujarat-based stocks alongside the promoter. The table uses the latest reported quarter for each. Astral has the deepest institutional backing, with FII and DII together holding 35.20% as of June 2026. Domestic institutions increased their holding over the past year in Torrent Pharma (from 9.28% to 12.87%), Zydus Lifesciences (from 10.86% to 11.28%) and Astral (from 14.90% to 21.31%).<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Promoter<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">FII<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">DII<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Public<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Quarter<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Torrent Pharma<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">60.78%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">17.97%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.87%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">8.38%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">July 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Zydus Lifesciences<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">75.01%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">7.04%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">11.28%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">6.66%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">September 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Astral<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">54.22%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">13.89%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">21.31%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">10.58%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">June 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_Weigh_in_Gujarat-based_Stocks\"><\/span><strong>Risks to Weigh in Gujarat-based Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Being careful with Gujarat-based stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:<\/p>\n<ul>\n<li>Pharma earnings depend on prescriptions and export pricing.<\/li>\n<li>Building product demand follows housing activity.<\/li>\n<li><strong>Valuation:<\/strong> Torrent Pharma trades at a PE of 81.26 against an industry PE of 36.42, so earnings need to keep growing to support the price.<\/li>\n<li><strong>Concentration:<\/strong> Holding all 3 names puts the allocation in one sector, so size each position to match your risk appetite.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Choose_Between_Gujarat-based_Stocks\"><\/span><strong>How to Choose Between Gujarat-based Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Picking from Gujarat-based stocks comes down to four checks, applied in order.<\/p>\n<ol>\n<li>Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.<\/li>\n<li>Compare each PE with the industry PE (36.42 to 36.61) and ask whether the growth rate justifies any gap.<\/li>\n<li>Track revenue growth, the operating margin and the return on equity in every quarterly result.<\/li>\n<li>Stagger entries across quarters and review institutional holding every reporting season.<\/li>\n<\/ol>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Torrent Pharma, Zydus Lifesciences and Astral live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among Gujarat-based stocks, Torrent Pharma stands out for the highest return on equity at 25.49%, Zydus Lifesciences for the lowest PE of the group at 24.78 and Astral for the strongest latest-quarter profit growth at 51.77%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing Gujarat-based stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Gujarat-based_Stocks_to_Watch\"><\/span><strong>Frequently Asked Questions on Gujarat-based Stocks to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_are_the_best_Gujarat-based_stocks_to_watch_for_multibagger_potential\"><\/span><strong>Which are the best Gujarat-based stocks to watch for multibagger potential?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Torrent Pharma, Zydus Lifesciences and Astral are the 3 names this list highlights, with market caps of Rs 1,75,196 crore, Rs 1,13,790 crore and Rs 38,753 crore respectively. Torrent Pharma is notable for the highest return on equity at 25.49%. Zydus Lifesciences stands out for the lowest PE of the group at 24.78. Astral offers the strongest latest-quarter profit growth at 51.77%. These are watchlist names for Gujarat-based stocks, not recommendations, so match each one to your own risk profile and time horizon.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Torrent_Pharma_a_good_stock_for_long-term_investors\"><\/span><strong>Is Torrent Pharma a good stock for long-term investors?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Torrent Pharma has a return on equity of 25.49%, a PE of 81.26 against an industry PE of 36.42 and a market cap of Rs 1,75,196 crore. Net profit has compounded at 28.79% a year since FY22, and FY26 revenue rose 20.34% while June 2026 quarter net profit grew 3.28%. Long-term returns in Gujarat-based stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Can_Zydus_Lifesciences_become_a_multibagger_from_here\"><\/span><strong>Can Zydus Lifesciences become a multibagger from here?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Zydus Lifesciences has already gained 113.38% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in Gujarat-based stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 21.24% a year since FY22, and FY26 revenue rose 17.64%. At a PE of 24.78 against an industry PE of 36.42, valuation should be checked against that growth before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_of_Torrent_Pharma_Zydus_Lifesciences_and_Astral\"><\/span><strong>What is the market cap of Torrent Pharma, Zydus Lifesciences and Astral?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 16 October 2026, Torrent Pharma has a market cap of Rs 1,75,196 crore, Zydus Lifesciences has a market cap of Rs 1,13,790 crore and Astral has a market cap of Rs 38,753 crore. Torrent Pharma is the largest of the group. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on Gujarat-based stocks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_risks_of_investing_in_Gujarat-based_stocks\"><\/span><strong>What are the risks of investing in Gujarat-based stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks are drug pricing in export markets, raw material costs and a slowdown in housing. Companies with strong brands and varied products handle these better. Torrent Pharma trades at a PE of 81.26 against an industry PE of 36.42, so earnings growth needs to hold up.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Torrent_Pharma_trading_at_a_PE_of_8126\"><\/span><strong>Why is Torrent Pharma trading at a PE of 81.26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Torrent Pharma&#8217;s PE of 81.26 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 25.49%, profit growth of 28.79% a year since FY22 and FY26 revenue growth of 20.34%, which also means the stock is more sensitive if growth slows. Investors in Gujarat-based stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_much_do_institutions_hold_in_Torrent_Pharma_Zydus_Lifesciences_and_Astral\"><\/span><strong>How much do institutions hold in Torrent Pharma, Zydus Lifesciences and Astral?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of the latest reported quarter, FII and DII together hold 30.84% of Torrent Pharma (17.97% and 12.87%), 18.32% of Zydus Lifesciences (7.04% and 11.28%) and 35.20% of Astral (13.89% and 21.31%). Rising institutional holding is a useful signal in Gujarat-based stocks, though it should be read with earnings trends rather than on its own.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which are the best Gujarat-based stocks to watch for multibagger potential?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Torrent Pharma, Zydus Lifesciences and Astral are the 3 names this list highlights, with market caps of Rs 1,75,196 crore, Rs 1,13,790 crore and Rs 38,753 crore respectively. Torrent Pharma is notable for the highest return on equity at 25.49%. Zydus Lifesciences stands out for the lowest PE of the group at 24.78. Astral offers the strongest latest-quarter profit growth at 51.77%. These are watchlist names for Gujarat-based stocks, not recommendations, so match each one to your own risk profile and time horizon.\"}},{\"@type\":\"Question\",\"name\":\"Is Torrent Pharma a good stock for long-term investors?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Torrent Pharma has a return on equity of 25.49%, a PE of 81.26 against an industry PE of 36.42 and a market cap of Rs 1,75,196 crore. Net profit has compounded at 28.79% a year since FY22, and FY26 revenue rose 20.34% while June 2026 quarter net profit grew 3.28%. Long-term returns in Gujarat-based stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.\"}},{\"@type\":\"Question\",\"name\":\"Can Zydus Lifesciences become a multibagger from here?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Zydus Lifesciences has already gained 113.38% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in Gujarat-based stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 21.24% a year since FY22, and FY26 revenue rose 17.64%. At a PE of 24.78 against an industry PE of 36.42, valuation should be checked against that growth before investing.\"}},{\"@type\":\"Question\",\"name\":\"What is the market cap of Torrent Pharma, Zydus Lifesciences and Astral?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 16 October 2026, Torrent Pharma has a market cap of Rs 1,75,196 crore, Zydus Lifesciences has a market cap of Rs 1,13,790 crore and Astral has a market cap of Rs 38,753 crore. Torrent Pharma is the largest of the group. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on Gujarat-based stocks.\"}},{\"@type\":\"Question\",\"name\":\"What are the risks of investing in Gujarat-based stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are drug pricing in export markets, raw material costs and a slowdown in housing. Companies with strong brands and varied products handle these better. Torrent Pharma trades at a PE of 81.26 against an industry PE of 36.42, so earnings growth needs to hold up.\"}},{\"@type\":\"Question\",\"name\":\"Why is Torrent Pharma trading at a PE of 81.26?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Torrent Pharma's PE of 81.26 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 25.49%, profit growth of 28.79% a year since FY22 and FY26 revenue growth of 20.34%, which also means the stock is more sensitive if growth slows. Investors in Gujarat-based stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.\"}},{\"@type\":\"Question\",\"name\":\"How much do institutions hold in Torrent Pharma, Zydus Lifesciences and Astral?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of the latest reported quarter, FII and DII together hold 30.84% of Torrent Pharma (17.97% and 12.87%), 18.32% of Zydus Lifesciences (7.04% and 11.28%) and 35.20% of Astral (13.89% and 21.31%). Rising institutional holding is a useful signal in Gujarat-based stocks, though it should be read with earnings trends rather than on its own.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>3 top Gujarat-based stocks compared on market cap, PE, ROE, growth and institutional holding: Torrent Pharma, Zydus Lifesciences and Astral.<\/p>\n","protected":false},"author":33,"featured_media":315622,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[13145,13144],"class_list":["post-315624","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-gujarat-based-sector","tag-gujarat-based-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["315622"],"rank_math_title":["Gujarat-based Stocks 2026: Torrent Pharma, Zydus Lifesciences"],"rank_math_description":["Gujarat-based stocks to watch for multibagger potential: Torrent Pharma, Zydus Lifesciences and Astral. Compare market cap, PE, ROE, growth and institutional holding."],"rank_math_focus_keyword":["Gujarat-based stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-top-gujarat-based-stocks-to-watch-for-future-multibagger-potential-torrent.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/315624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=315624"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/315624\/revisions"}],"predecessor-version":[{"id":315626,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/315624\/revisions\/315626"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/315622"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=315624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=315624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=315624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}